Search
Megestrol acetate
go.drugbank.com/drugs/DB00351ApprovedInvestigationalVet approvedA progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. … It has also been used in the palliative treatment of breast cancer.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSynonyms: MGAEstradiol valerate
go.drugbank.com/drugs/DB13956ApprovedInvestigationalVet approvedThe primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. … [DB00783] is commonly produced with an ester side-chain as endogenous estradiol has very low oral bioavailability on its own (2-10%).
Mixtures: DIVINA 2 MG + 2 MG /10 MG TABLET, 21 ADET, DIVINA 2 MG + 2 MG /10 MG TABLET, 21 ADETCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesInsulin glargine
go.drugbank.com/drugs/DB00047ApprovedInvestigationalAs of 2015, insulin glargine was reformulated by Sanofi as the product Toujeo in an extra-concentrated form containing 300IU/mL (compared to 100IU/mL contained in Lantus). … Use of the higher concentrated Toujeo as compared to Lantus results in slightly different pharmacokinetics, with a later onset (up to 6 hours) and duration of action (up to 30 hours).
Mixtures: SOLİQUA SOLOSTAR 100 U/ML + 50 MCG/ML SC ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 5 KALEM, โซลิควา (100 ยูนิต/มิลลิลิตร + 50 ไมโครกรัม/มิลลิลิตร)Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersApremilast
go.drugbank.com/drugs/DB05676ApprovedInvestigationalIt belongs to the same drug class as [Roflumilast] and [Crisaborole].[A181244,L7495] Initially approved in 2014, it is marketed by Celgene. … Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases.
Mixtures: OTEZLA (10 MG 20 MG 30 MG), OTEZLA (10 MG 20 MG 30 MG)Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesIsoconazole
go.drugbank.com/drugs/DB08943ApprovedIsoconazole is an azole antifungal drug that has similar effectiveness to clotrimazole in the treatment of foot and vaginal infections.
Mixtures: TRODERM 10 MG/G+1 MG/G KREM ,15 G, TİNAGEN 1 MG+10 MG/1 G DERİ KREMİ, 15 GProducts: GYNO-TRAVOGEN OVULE 600 mg, GYNO-TRAVOGEN 600 MG OVUL, 1 ADETGlipizide
go.drugbank.com/drugs/DB01067ApprovedInvestigational[A179485] Glipizide was first approved by the FDA in 1994 and is available in extended-release tablets under the brand name Glucotrol®, as well as in combination with metformin under the brand name Metaglip … It was first introduced in 1984 [A179491] and is available in various countries including Canada and the U.S.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesSynonyms: 1-cyclohexyl-3-({p-[2-(5-methylpyrazinecarboxamido)ethyl]phenyl}sulfonyl)urea, N-{4-[β-(5-methylpyrazine-2-carboxamido)ethyl]benzenesulphonyl}-N'-cyclohexylureaBelimumab
go.drugbank.com/drugs/DB08879ApprovedInvestigational[L42630] Belimumab was first approved by the FDA on March 9, 2011,[A251495] making it the newest drug to be approved for the treatment of SLE in more than 50 years. … [L42630] BLyS levels are often elevated in immunodeficient and autoimmune disorders, such as systemic lupus erythematosus (SLE).
Products: BENLYSTA 200 MG / 1 ML, BENLYSTA SUBCUTÁNEO 200 MG / 1 MLTriethylenetetramine
go.drugbank.com/drugs/DB06824ApprovedInvestigationalTETA was first developed in Germany in 1861 and its chelating properties were first recognized in 1925. … [L41730] TETA has been investigated in clinical trials for the treatment of heart failure in patients with diabetes.[A18804,A19332,A19333,A19334,A19335]
Products: NOVİLS 250 MG SERT KAPSÜL, 100 ADET, WİLENTİN 250 MG SERT KAPSÜL, 100 ADETCefradine
go.drugbank.com/drugs/DB01333ApprovedWithdrawnA semi-synthetic cephalosporin antibiotic.
Synonyms: (6R,7R)-7-((R)-2-Amino-2-(1,4-cyclohexadien-1-yl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, (6R,7R)-7-{[(2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acidCategories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersDonepezil
go.drugbank.com/drugs/DB00843ApprovedInvestigationalDonepezil was first approved by the FDA in 1996, and its extended-release form was approved in combination with [Memantine] in 2014 to manage moderate and severe forms of Alzheimer's dementia. … In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990.
Mixtures: EBICOMB 5 MG/10 MG EFERVESAN TABLET, 100 ADET, EBICOMB 10 MG/10 MG EFERVESAN TABLET, 100 ADETCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates